Page not found

ICON reports first quarter 2026 results. Quarter one revenue of $2,034.0 million. Net business wins in the quarter of $2,880 million; a net book-to-bill of 1.42. Read more https://ow.ly/rfbO50Zg1vj

Recent regulatory shifts have critical implications for how biosimilar developers generate and prioritise information. Read ICON’s latest article in PharmTech Magazine, to learn what these changes mean for data collect...

ICON will be attending #SCDMChina, taking place from 3 - 4 July in Shanghai, China. Stop by booth \#6 to connect with our team and discover how ICON is transforming clinical research with innovative, data-driven solutio...

ICON has selected Microsoft as a preferred technology partner to power AI-enabled clinical development. This partnership incorporates an enterprise-wide deployment of Microsoft 365 Copilot along with an enterprise-grade ...

Osivelotor is an oral investigational drug for the treatment of sickle cell disease (SCD) designed to inhibit hemoglobin polymerization. In a phase 1, open-label ADME study conducted in healthy participants at ICON’s cli...

Cut point determination is essential in ADA assay development, and while statistical methods like Tukey’s test can lead to ultra-low cut points (ULCPs), concerns around reliability and false positives may be overstated. ...

ICON Biotech will be onsite at CTO East Coast, taking place 30 June – 1 July at the Boston Marriott Burlington, MA. As a leading provider of integrated clinical research services, ICON supports oncology and biotech compa...

We are excited to announce that Cytek Aurora 5L Spectral Flow Cytometers are now live in our bioanalytical labs in the Netherlands and US. With the new addition we are offering: 1) Development/transfer, validation, and ...

Modern biologics manufacturing demands regulatory strategies that keep pace with evolving modalities, data driven controls and continuous processing. This article outlines practical considerations for aligning viral saf...

Real-time clinical trials are moving from concept to reality, led by the FDA’s latest initiative to enable near real-time data sharing and AI-enabled decision-making. But what does this mean in a global regulatory landsc...

Critical care trials push the limits, with tight timelines, shifting patient status, and consent challenges that don’t fit traditional models. Success depends on protocols that reflect real ICU dynamics, operations that ...

ICON Laboratories now offers comprehensive blood-based biomarker testing for Alzheimer’s disease and neurodegenerative disorders—supporting earlier detection, improved patient access, and smarter clinical development str...